SCHEMBL1147358

SCHEMBL1147358

CC(C)c1ccc(NC(=O)C2(N)CCN(Cc3ccc(F)cc3)CC2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 2/20 0.52
ALDH1A1 P00352 5/20 0.51
MAPK1 P28482 2/20 0.51
MAPT P10636 2/20 0.51
GAA P10253 1/20 0.51
BCHE P06276 3/20 0.50
PANK3 Q9H999 1/20 0.47
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
LMNA P02545 1/20 0.47
HTT P42858 1/20 0.46
ACHE P22303 1/20 0.46
CACNA1H O95180 1/20 0.45
NTRK1 P04629 1/20 0.45
KDM4E B2RXH2 1/20 0.45
HPGD P15428 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
MCHR1 Q99705 1/20 0.45
NPY2R P49146 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1147270 0.99 FAAH (0.51) FAAHALDH1A1MAPK1MAPTGAA
SCHEMBL1147324 0.94 FAAH (0.57) FAAHALDH1A1MAPK1MAPTGAA
Hydrochloric Acid SCHEMBL1147243 0.93 FAAH (0.56) FAAHALDH1A1MAPK1MAPTGAA
SCHEMBL1147018 0.90 ALDH1A1 (0.61) FAAHALDH1A1MAPK1MAPTGAA
SCHEMBL1147420 0.90 FAAH (0.53) FAAHALDH1A1MAPK1MAPTGAA
SCHEMBL1147220 0.89 FAAH (0.50) FAAHALDH1A1MAPK1MAPTGAA
SCHEMBL1147016 0.88 HIF1A (0.52) FAAHALDH1A1MAPK1MAPTGAA
Hydrochloric Acid SCHEMBL1147317 0.88 FAAH (0.49) FAAHALDH1A1MAPK1MAPTGAA
SCHEMBL1147126 0.88 SSTR5 (0.55) FAAHALDH1A1MAPK1MAPTGAA
Hydrochloric Acid SCHEMBL1146746 0.87 HIF1A (0.51) FAAHALDH1A1MAPK1MAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011012602-A1 PIPERIDINE DERIVATIVES AND THEIR USE TO TREAT OBESITY, DIABETES, DYSLIPIDEMIA AND ATHEROSCLEROSIS F. HOFFMANN-LA ROCHE AG (CH) 2011-02-03 WO claimed
US-8399676-B2 Piperidine derivatives HOFFMAN-LA ROCHE INC. (US) 2013-03-19 US disclosed
US-8399676-B2 Piperidine derivatives HOFFMAN-LA ROCHE INC. (US) 2013-03-19 US disclosed
US-20110028515-A1 NEW PIPERIDINE DERIVATIVES HOFFMANN-LA ROCHE, INC. 2011-02-03 US disclosed
US-20110028515-A1 NEW PIPERIDINE DERIVATIVES HOFFMANN-LA ROCHE, INC. 2011-02-03 US disclosed
US-20110028515-A1 NEW PIPERIDINE DERIVATIVES HOFFMANN-LA ROCHE, INC. 2011-02-03 US disclosed
WO-2011012602-A1 PIPERIDINE DERIVATIVES AND THEIR USE TO TREAT OBESITY, DIABETES, DYSLIPIDEMIA AND ATHEROSCLEROSIS F. HOFFMANN-LA ROCHE AG (CH) 2011-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028515-A1 NEW PIPERIDINE DERIVATIVES ADRA1D, ADORA1, H1-0 FAAH 2059/4885ALDH1A1 45/4885MAPK1 2518/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.